COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the seven research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $17.00.

CMPS has been the subject of several analyst reports. HC Wainwright reiterated a "buy" rating on shares of COMPASS Pathways in a research report on Monday, June 23rd. Cantor Fitzgerald restated an "overweight" rating and issued a $12.00 target price on shares of COMPASS Pathways in a research report on Tuesday, May 27th. Finally, Evercore ISI restated an "in-line" rating and issued a $6.00 target price (down from $11.00) on shares of COMPASS Pathways in a research report on Monday, June 23rd.

COMPASS Pathways Stock Performance

Shares of NASDAQ CMPS opened at $3.31 on Tuesday. The company has a current ratio of 10.18, a quick ratio of 10.18 and a debt-to-equity ratio of 0.11. The stock has a 50 day simple moving average of $3.98 and a 200-day simple moving average of $3.79. The company has a market cap of $309.68 million, a PE ratio of -1.66 and a beta of 2.12. COMPASS Pathways has a 12-month low of $2.25 and a 12-month high of $8.54.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.03. On average, equities research analysts forecast that COMPASS Pathways will post -2.33 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CMPS. RTW Investments LP bought a new position in shares of COMPASS Pathways in the fourth quarter valued at $11,714,000. Nantahala Capital Management LLC increased its holdings in shares of COMPASS Pathways by 182.9% in the first quarter. Nantahala Capital Management LLC now owns 2,829,232 shares of the company's stock valued at $8,092,000 after buying an additional 1,829,232 shares in the last quarter. Vivo Capital LLC increased its holdings in shares of COMPASS Pathways by 109.1% in the first quarter. Vivo Capital LLC now owns 3,362,385 shares of the company's stock valued at $9,616,000 after buying an additional 1,754,385 shares in the last quarter. Altium Capital Management LLC bought a new position in shares of COMPASS Pathways in the fourth quarter valued at $5,384,000. Finally, Woodline Partners LP increased its holdings in shares of COMPASS Pathways by 279.9% in the first quarter. Woodline Partners LP now owns 1,754,856 shares of the company's stock valued at $5,019,000 after buying an additional 1,292,927 shares in the last quarter. Institutional investors own 46.19% of the company's stock.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.